FDA Seeks Input on Tracking Imported Meds – Yawn?
Published Date: 4/16/2026
Notice
Summary
The FDA wants your thoughts on how they collect info about importing prescription drugs. This affects drug companies and anyone involved in bringing meds into the U.S. You’ve got until June 15, 2026, to share your comments—no cost to join, just your voice! It’s all about making sure the rules stay clear and helpful.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
Recordkeeping Burden on Import Programs
The FDA estimates the information collection will require about 100 responses and 6,040 hours of recordkeeping work each year. The notice shows Subpart B involves 40 recordkeepers with 60 total records and an average burden of 72 hours per recordkeeping (4,320 hours total), and Subpart C involves 40 recordkeepers with 40 total records and an average burden of 43 hours per recordkeeping (1,720 hours total).
Rules for SIP Submission and Review
21 CFR part 251 sets procedures that Section 804 Importation Program (SIP) sponsors must follow when submitting plans for time-limited programs to import drugs from Canada. The regulations also establish FDA review and authorization criteria, requirements for eligible prescription drugs and for entities engaging in importation, and provide for certain exempt eligible prescription drugs under section 502(f)(1).
Statutory Goal To Lower Drug Costs
Section 804 of the Federal Food, Drug, and Cosmetic Act is intended to reduce the cost of covered products to American consumers without imposing additional risk to public health and safety. The FDA’s information collection supports implementation of that section and the related part 251 regulations.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He didn’t respond to the FDA’s warning, so the ban started on May 15, 2026. If he wants to end the ban early, he can apply anytime, but must follow special rules to keep his info private.
2026-09533 — Biomarker Incubator: Urinary Kidney Safety Biomarkers; Request for Information
The FDA wants your help to improve tests that spot kidney damage caused by medicines. They’re asking researchers, doctors, and companies to share data by July 13, 2026, so they can make these kidney safety markers better and faster. This could lead to safer drugs and smarter health checks, benefiting patients and the medical community alike.
2026-09508 — Azodicarbonamide (ADA); Request for Information
The FDA is asking for info about azodicarbonamide (ADA), a chemical used in some foods and food packaging, to check if it’s still safe. Food makers, scientists, and anyone with data should share what they know by July 13, 2026. This review could lead to changes in how ADA is used, affecting food companies and possibly costs down the line.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This update affects drug makers and helps keep medicine safe by improving how side effects are tracked. You’ve got until July 13, 2026, to share your comments—no cost to join, just your voice!
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If renewed, the company can keep marketing them this way, with the comment period starting May 13, 2026.
2026-09507 — Butylated Hydroxytoluene (BHT); Request for Information
The FDA wants to know more about how butylated hydroxytoluene (BHT), a chemical used in food and food packaging, is being used and if it’s still safe. They’re asking companies, scientists, and the public to share any info by July 13, 2026. This could lead to changes in rules that affect food makers and might impact what’s allowed in your snacks and packaging.
Previous / Next Documents
Previous: 2026-07420 — Publishing.com, LLC, Christian Mikkelsen, and Rasmus Mikkelsen; Analysis of Proposed Consent Order To Aid Public Comment
Publishing.com, LLC and the Mikkelsen brothers are facing charges for unfair or misleading business practices. They’ve agreed to stop these actions under a new deal, and the public has until May 18, 2026, to share their thoughts. This means changes are coming to how they operate, with no direct money penalties mentioned yet.
Next: 2026-07422 — Determination of Regulatory Review Period for Purposes of Patent Extension; UNLOXCYT
The FDA has set the official review period for UNLOXCYT, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind UNLOXCYT and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s effort during review, you have until mid-2026 to speak up—potentially impacting patent length and market exclusivity.